Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plasma Concentrations Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

EryDex Pharmacokinetics in Healthy Volunteers

NCT01925859
View directory record Official record
Conditions
Healthy
Interventions
EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Jul 22, 2026, 10:45 PM EDT
Terminated Not applicable Interventional

Moderate Intensity Exercise and Phenylketonuria

NCT01904708
View directory record Official record
Conditions
Phenylketonuria, PKU
Interventions
Acute Moderate Intensity Exercise
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
14 Years to 17 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 4 Interventional

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

NCT00343876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 22, 2026, 10:45 PM EDT
Recruiting Phase 4 Interventional

Dapagliflozin Plus Pioglitazone in T1DM

NCT03878459
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

NCT04302896
View directory record Official record
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jul 22, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cyclic Variation in Micronutrient Concentrations and Plasma Volume

NCT03422809
View directory record Official record
Conditions
Plasma Volume, Micronutrients, Menstrual Cycle
Interventions
Not listed
Lead sponsor
Alison Gernand
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

NCT02695446
View directory record Official record
Conditions
Acne
Interventions
Minocycline
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
14 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 22, 2026, 10:45 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth

NCT03292731
View directory record Official record
Conditions
Preterm Birth
Interventions
17-Hydroxyprogesterone caproate 250mg or 500 mg., Safety study of 500 mg dose.
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

NCT00013663
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Jul 22, 2026, 10:45 PM EDT
Recruiting Phase 4 Interventional

Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy

NCT03737292
View directory record Official record
Conditions
Pain, Postoperative, Pharmacokinetics
Interventions
Exparel, Bupivacaine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

NCT02082236
View directory record Official record
Conditions
Healthy
Interventions
Treatment Arm A: Sufenta®, Treatment B: Sufentanil SSM 30 mcg, Treatment C: SSM 15 mcg, Treatment D: SSM 30 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

NCT06476834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

NCT00485407
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 16 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Jul 22, 2026, 10:45 PM EDT
Completed No phase listed Observational

Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine

NCT00581932
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
Delwyn D. Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Menthol Electronic Cigarettes vs Combustible Menthol Cigarettes and Nicotine Gum

NCT02664012
View directory record Official record
Conditions
Smoking
Interventions
Own Brand Menthol Cigarette, Electronic Menthol Cigarette #1, Electronic Menthol Cigarette #2, Electronic Menthol Cigarette #3, Leading U.S. Nicotine Gum
Other
Lead sponsor
R.J. Reynolds Vapor Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

NCT05282030
View directory record Official record
Conditions
Renal Impairment
Interventions
tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of TLR4 on Lipid-induced Insulin Resistance

NCT02321111
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Eritoran, D5W (5% Dextrose in water)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

NCT04710407
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TBPM-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery

NCT02058979
View directory record Official record
Conditions
Plasma Concentration of Antibiotics
Interventions
BOLUS INFUSION (Ancef), CONTINUOUS INFUSION (Ancef)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RE104 Clinical Lactation Study

NCT06659263
View directory record Official record
Conditions
Lactation
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 22, 2026, 10:45 PM EDT